Introduction: Oncology drug development relies heavily on in vivo models such as patient derived xenografts (PDX) for preclinical drug efficacy testing. However, PDX models are limited by long tumor establishment times, high engraftment failure rates, high experimental costs [1] and arbitrary drug dosing. Thus, developing a systematic pipeline to prioritize the most efficacious drugs at […]
